Pfizer’s cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study. The drug combination showed a significant improvement in the overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of the presence of a mutation, … Read more
